Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the effect on obtaining authorisations for new drugs of the UK withdrawing from the European Medicines Agency.

The extent to which European Medicines Agency procedures will apply in the United Kingdom after we have exited the European Union will be subject to negotiations. Whatever the outcome of negotiations, the Government will ensure that we have a regulatory system that protects the best interests of patients – without regulatory delay in the approval of new medicines - and encourages innovation.